Table 2.
Characteristics of surgical techniques
| NPDS | Ex-PRESS | TBC | Ahmed | Baerveldt | CPC | |
|---|---|---|---|---|---|---|
| n = 18 | n = 8 | n = 3 | n = 13 | n = 4 | n = 13 | |
| Previous glaucoma surgeries | ||||||
| First | 17 | 6 | 2 | 5 | – | 7 |
| Second | 1 | 2 | 1 | 6 | 3 | 1 |
| Third | – | – | – | 2 | 1 | 5 |
| Antifibrotic agents n (%) | ||||||
| 5-FU | 9 (50) | 5 (63) | 2 (66) | – | – | – |
| MMC | 8 (44.4) | – | 1 (33) | – | – | – |
| N/S | 1 (5.6) | 3 (37) | – | – | – | – |
| Ologen | 3 (16.7) | 3 (37.5) | 1 (33) | – | – | – |
| Implants | ||||||
| SKGel | 1 (5.6) | – | – | – | – | – |
| T-Flux | 9 (50) | – | – | – | – | – |
| Esnoper | 7 (38.9) | – | – | – | – | – |
| N/S | 1 (5.6) | – | – | – | – | – |
| Number of treatments† | ||||||
| Median (IQR) | – | – | – | – | – | 1 (1–2) |
| Follow-up, months | ||||||
| Mean (min–max) | 15.6 (1–36) | 11.6 (3–24) | 27 (12–42) | 22.8 (6–36) | 18 (3–24) | 15.7 (6–42) |
| IOP, mm Hg (mean ± SD) | ||||||
| Baseline | 30.4 ± 7.9 | 29 ± 10.3 | 27.3 ± 11.2 | 30.0 ± 9.6 | 31.5 ± 11.8 | 35.0 ± 7.8 |
| Reduction, last follow-up visit | −8 ± 13.3 | −12 ± 10 | −2.0 ± 9.8 | −10.5 ± 14.3 | −13.0 ± 24.1 | −18.1 ± 9.0 |
| Glaucoma medications. median (IQR) | ||||||
| Baseline | 3 (3–3) | 3 (2.5–3) | 4 (3–4) | 3 (2–3) | 3 (1.5–3.5) | 3 (2–3) |
| Reduction, last follow-up visit | −0.5 (−1 to 0) | −2 (−2 to −0) | 0 (−1 to 0) | −2 (−3 to 0) | −0 (−3 to 0.0) | −2 (−3 to 0) |
| Oral acetazolamide n (%) | ||||||
| Preoperative | 11 (61.1) | 0 (0) | 2 (66.7) | 6 (46.2) | 3 (75.0) | 9 (69.2) |
| Postoperative | 1 (7.1) | 0 (0) | 1 (33.3) | 2 (15.4) | 1 (25.0) | 1 (8.3) |
CPC, cyclophotocoagulation; IOP, intraocular pressure; IQR, interquartile range; MMC, mitomycin-C; NPDS, non-penetrating deep sclerectomy; N/S, non-specified; SD, standard deviation; TBC, trabeculectomy; 5-FU, 5-fluorouracil
†
Applies only to CPC